Pamidronate disodium is a second-generation nitrogen-containing bisphosphonate that inhibits bone loss. It significantly inhibits subchondral bone loss in early osteoarthritis by upregulating osteoprotegerin expression and inhibiting RANKL, MMP-9, and TLR-4 expression in cartilage and subchondral bone, thereby alleviating cartilage degeneration. This compound also inhibits Wnt and β-catenin signaling and is suitable for research on osteoporosis and osteosarcoma.
- Inhibits bone loss.
- Upregulates osteoprotegerin expression.
- Inhibits RANKL, MMP-9, and TLR-4 expression.
- Alleviates cartilage degeneration.
- Inhibits Wnt and β-catenin signaling.
- Applicable for research on osteoporosis and osteosarcoma.
- Inhibits osteosarcoma cell viability (0.001-1000 μM, 72 h).
- Improves bone structure and alleviates cartilage degenerative changes in vivo.